FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gerard Groenewegen

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Cohort Studies

Co-author Network

Publications

TOP 3
Gerard Groenewegen; J Haanen; J Vermaat; B de Gast; Rachel H Giles; M Walraven; Els O Witteveen; Emile E Voest
Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.
Petronella O Witteveen; Koen J C van der Mijn; Maartje Los; Roelien H Kronemeijer; Gerard Groenewegen; Emile E Voest
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
H Wessels; Alexander de Graeff; Gerard Groenewegen; K Wynia; M de Heus; J B H Vos; P Tjia; Cas L J J Kruitwagen; S C C M Teunissen; Emile E Voest
Impact of integration of clinical and outpatient units on cancer patient satisfaction.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gerard Groenewegen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Gerard Groenewegen; J Haanen; J Vermaat; B de Gast; Rachel H Giles; M Walraven; Els O Witteveen; Emile E Voest
Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.
British journal of cancer 2012;106(2):284-9.
2010: Petronella O Witteveen; Koen J C van der Mijn; Maartje Los; Roelien H Kronemeijer; Gerard Groenewegen; Emile E Voest
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
Neoplasia (New York, N.Y.) 2010;12(11):941-5.
2010: H Wessels; Alexander de Graeff; Gerard Groenewegen; K Wynia; M de Heus; J B H Vos; P Tjia; Cas L J J Kruitwagen; S C C M Teunissen; Emile E Voest
Impact of integration of clinical and outpatient units on cancer patient satisfaction.
International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua 2010;22(5):358-64.
2009: Bartjan de Hoop; Hester A Gietema; Bram van Ginneken; Pieter Zanen; Gerard Groenewegen; Mathias Prokop
A comparison of six software packages for evaluation of solid lung nodules using semi-automated volumetry: what is the minimum increase in size to detect growth in repeated CT examinations.
European radiology 2009;19(4):800-8.
2005: Daniel W Rea; J W R Nortier; Wim W ten Bokkel Huinink; SJ Falk; D J Richel; Timothy S Maughan; Gerard Groenewegen; JM Smit; Neil M Steven; J M Bakker; D Semiond; David J Kerr; Cornelis J A Punt
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1123-32.
2004: Thomas Kerbusch; Gerard Groenewegen; Ron A A Mathôt; Virginie M M Herben; Wim W ten Bokkel Huinink; M Swart; B Ambaum; Hilde Rosing; Sindy Jansen; Emile E Voest; Jos H Beijnen; J H M Schellens
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
British journal of cancer 2004;90(12):2268-77.
2003: Roland Repp; Heidi H van Ojik; Thomas Valerius; Gerard Groenewegen; G Wieland; C Oetzel; Bernhard Stockmeyer; W Becker; M Eisenhut; H Steininger; YM Deo; Geert H Blijham; Joachim R Kalden; Jan G J van de Winkel; Martin Gramatzki
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
British journal of cancer 2003;89(12):2234-43.
2003: Laurens V Beerepoot; Els O Witteveen; Gerard Groenewegen; William E Fogler; B Kim Lee Sim; Carolyn Sidor; Bernard A Zonnenberg; Franz Schramel; Martijn F B G Gebbink; Emile E Voest
Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4025-33.
2003: Bernard A Zonnenberg; Gerard Groenewegen; Todd J Janus; Terri W Leahy; Rod A Humerickhouse; Jeffrey D Isaacson; Robert A Carr; Emile E Voest
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2965-72.
2003: Natascha C V Verra; R Jansen; Gerard Groenewegen; Henk Mallo; Marie José Kersten; Axel Bex; Florry A Vyth-Dreese; Johan Sein; Willeke F van de Kasteele; Willem Nooijen; M de Waal; Simon Horenblas; Gijsbert C De Gast
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
British journal of cancer 2003;88(9):1346-51.
2002: Gerard Groenewegen; Andries C Bloem; Gijsbert C De Gast
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Cancer immunology, immunotherapy : CII 2002;51(11-12):630-6.
2002: Jetske M Meerum Terwogt; Gerard Groenewegen; Dick Pluim; Marc Maliepaard; Matthijs M Tibben; Albert Huisman; Wim W ten Bokkel Huinink; Margaret Schot; Helen Welbank; Emile E Voest; Jos H Beijnen; Jan M Schellens
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Cancer chemotherapy and pharmacology 2002;49(3):201-10.
2000: Gerard Groenewegen; S Osanto; H J van der Rhee; Cornelis J A Punt
[Interferon for adjuvant therapy in melanoma; although approved, not indicated].
Nederlands tijdschrift voor geneeskunde 2000;144(45):2160-2.
2000: C M L van Herpen; Rob L Jansen; Wim H J Kruit; Klaas Hoekman; Gerard Groenewegen; S Osanto; P H M De Mulder
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
British journal of cancer 2000;82(4):772-6.
1999: Gerard Groenewegen; Gijsbert C De Gast
GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy.
European journal of cancer (Oxford, England : 1990) 1999;35 Suppl 3():S23-4.
1999: Arjan W Griffioen; CA Damen; Kevin H Mayo; AF Barendsz-Janson; Stefano Martinotti; Geert H Blijham; Gerard Groenewegen
Angiogenesis inhibitors overcome tumor induced endothelial cell anergy.
International journal of cancer. Journal international du cancer 1999;80(2):315-9.
1998: I A Relou; CA Damen; Daisy W J van der Schaft; Gerard Groenewegen; Arjan W Griffioen
Effect of culture conditions on endothelial cell growth and responsiveness.
Tissue & cell 1998;30(5):525-30.
1997: S M Hellwig; CA Damen; N P van Adrichem; Geert H Blijham; Gerard Groenewegen; Arjan W Griffioen
Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors.
Cancer letters 1997;120(2):203-11.
1997: Heidi H van Ojik; Roland Repp; Gerard Groenewegen; Thomas Valerius; Jan G J van de Winkel
Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
Cancer immunology, immunotherapy : CII 1997;45(3-4):207-9.
1997: Arjan W Griffioen; Marieke Coenen; CA Damen; S M Hellwig; D H van Weering; W Vooys; Geert H Blijham; Gerard Groenewegen
CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells.
Blood 1997;90(3):1150-9.
1996: Arjan W Griffioen; CA Damen; Geert H Blijham; Gerard Groenewegen
Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium.
Blood 1996;88(2):667-73.
1996: Arjan W Griffioen; CA Damen; S Martinotti; Geert H Blijham; Gerard Groenewegen
Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors.
Cancer research 1996;56(5):1111-17.
1996: Arjan W Griffioen; CA Damen; Geert H Blijham; Gerard Groenewegen
Endoglin/CD 105 may not be an optimal tumor endothelial treatment target.
Breast cancer research and treatment 1996;39(2):239-42.